



ELSEVIER

Contents lists available at [ScienceDirect](#)

Clinical Biochemistry

journal homepage: [www.elsevier.com/locate/clinbiochem](http://www.elsevier.com/locate/clinbiochem)



Corrigendum

Corrigendum to 'IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?' *Clinical Biochemistry* 61 (2018) 34–39



Lucie Petrova<sup>a,\*</sup>, Filip Vrbacky<sup>b</sup>, Miriam Lanska<sup>b</sup>, Alzbeta Zavrelova<sup>b</sup>, Pavel Zak<sup>b</sup>, Katerina Hrochova<sup>a</sup>

<sup>a</sup> *Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic*

<sup>b</sup> *4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic*

The authors regret that we inadvertently omitted the citation for Table 1, section B. The missing source is as follows:

A. Pardanani, T.L. Lasho, C.M. Finke, M. Mai, R.F. McClure, A. Tefferi, IDH1 and IDH2 mutation analysis in chronic- and blast-phase

myeloproliferative neoplasms,

*Leukemia* 24 (2010) 1146–1151. doi:<https://doi.org/10.1038/leu.2010.77>.

The authors would like to apologize for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.clinbiochem.2018.08.012>

\* Corresponding author.

E-mail address: [lucie.petrova@fnhk.cz](mailto:lucie.petrova@fnhk.cz) (L. Petrova).

<https://doi.org/10.1016/j.clinbiochem.2018.10.005>

Available online 16 October 2018

0009-9120/ © 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.